- Home
- CANF vs ANY Comparison
CANF vs ANY Comparison
Compare CANF & ANY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- ANY
- Stock Information
- Founded
- CANF 1994
- ANY N/A
- Country
- CANF Israel
- ANY United States
- Employees
- CANF N/A
- ANY N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- ANY Finance: Consumer Services
- Sector
- CANF Health Care
- ANY Finance
- Exchange
- CANF Nasdaq
- ANY Nasdaq
- Market Cap
- CANF 14.4M
- ANY 14.7M
- IPO Year
- CANF N/A
- ANY N/A
- Fundamental
- Price
- CANF $1.97
- ANY $0.88
- Analyst Decision
- CANF Strong Buy
- ANY Strong Buy
- Analyst Count
- CANF 2
- ANY 1
- Target Price
- CANF $14.00
- ANY $3.00
- AVG Volume (30 Days)
- CANF 116.8K
- ANY 246.0K
- Earning Date
- CANF 11-15-2024
- ANY 11-11-2024
- Dividend Yield
- CANF N/A
- ANY N/A
- EPS Growth
- CANF N/A
- ANY N/A
- EPS
- CANF N/A
- ANY N/A
- Revenue
- CANF $667,000.00
- ANY $25,026,000.00
- Revenue This Year
- CANF $356.93
- ANY N/A
- Revenue Next Year
- CANF N/A
- ANY N/A
- P/E Ratio
- CANF N/A
- ANY N/A
- Revenue Growth
- CANF N/A
- ANY 121.94
- 52 Week Low
- CANF $1.81
- ANY $0.57
- 52 Week High
- CANF $4.69
- ANY $4.09
- Technical
- Relative Strength Index (RSI)
- CANF 35.55
- ANY 48.27
- Support Level
- CANF $1.87
- ANY $0.84
- Resistance Level
- CANF $2.04
- ANY $1.04
- Average True Range (ATR)
- CANF 0.15
- ANY 0.06
- MACD
- CANF 0.00
- ANY 0.00
- Stochastic Oscillator
- CANF 18.18
- ANY 19.26
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About ANY Sphere 3D Corp.
Sphere 3D Corp provides solutions for stand-alone storage and technologies that converge the traditional silos of compute, storage, and network into integrated hyper-converged or converged solution. Its Disk systems include HVE Converged and Hyper-converged Infrastructure. It generates the majority of its revenue from the services it offers. All of its revenue comes from the Americas. The Company has two operating segments: Digital Mining and Service and Product. The Digital Mining segment generates revenue from the digital currency, it earns through its bitcoin mining activities. The Service and Product segment generates revenue from long-term customer contracts for service contracts and extended service contract and the sale of products related to the Company's data storage product line.